Your browser doesn't support javascript.
loading
Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease.
Sezen, Duygu; Verma, Vivek; He, Kewen; Abana, Chike O; Barsoumian, Hampartsaum; Ning, Matthew S; Tang, Chad; Hurmuz, Pervin; Puebla-Osorio, Nahum; Chen, Dawei; Tendler, Irwin; Comeaux, Nathan; Nguyen, Quynh-Nhu; Chang, Joe Y; Welsh, James W.
Afiliação
  • Sezen D; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Radiation Oncology, Koc University School of Medicine, Istanbul, Turkey.
  • Verma V; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • He K; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, Shandong, People's Republic of China.
  • Abana CO; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Barsoumian H; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Ning MS; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Tang C; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Hurmuz P; Department of Radiation Oncology, Hacettepe University School of Medicine, Ankara, Turkey.
  • Puebla-Osorio N; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Chen D; Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, Shandong, People's Republic of China.
  • Tendler I; Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Comeaux N; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Nguyen QN; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Chang JY; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Welsh JW; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: jwelsh@mdanderson.org.
Semin Radiat Oncol ; 31(3): 217-226, 2021 07.
Article em En | MEDLINE | ID: mdl-34090648
ABSTRACT
Metastatic cancer is inherently heterogeneous, and patients with metastatic disease can experience vastly different oncologic outcomes depending on several patient- and disease-specific characteristics. Designing trials for such a diverse population is challenging yet necessary to improve treatment outcomes for metastatic-previously thought to be incurable-disease. Here we review core considerations for designing and conducting clinical trials involving radiation therapy and immunotherapy for patients with metastatic cancer.
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoterapia / Neoplasias Limite: Humans Idioma: En Revista: Semin Radiat Oncol Assunto da revista: NEOPLASIAS / RADIOLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Turquia
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoterapia / Neoplasias Limite: Humans Idioma: En Revista: Semin Radiat Oncol Assunto da revista: NEOPLASIAS / RADIOLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Turquia